ROG.SW in “The Dollar Loses Its Exceptionalism”
Roche Holding
A stronger franc reduces the reported value of Roche's dollar and other foreign-currency pharmaceutical sales.
ROG.SW impact map — “The Dollar Loses Its Exceptionalism”
How this story travels from the headline to ROG.SW’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading ROG.SW impact map…
No stored price history yet — refresh it from the admin desk.
Full story
The Dollar Loses Its Exceptionalism
Fiscal risk and narrowing rate differentials are redirecting capital toward non-dollar assets and punishing currency-sensitive exporters.
BEAR side — A stronger franc reduces the reported value of Roche's dollar and other foreign-currency pharmaceutical sales.
Read the full The Dollar Loses Its Exceptionalism storyBull side
1 story- China Becomes Pharma's Global R&D Engine
ROG.SW in “China Becomes Pharma's Global R&D Engine”
Not enough historyExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Roche can combine China-originated drug candidates with its diagnostics, trial network and global oncology franchise.
Bear side
3 stories- America Imports the World's Drug Prices
ROG.SW in “America Imports the World's Drug Prices”
Not enough historyExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Roche's oncology and specialty-drug economics depend heavily on preserving premium pricing in the United States.
- Viewing
ROG.SW in “The Dollar Loses Its Exceptionalism”
Not enough historyExposure: not rated yetFiscal risk and narrowing rate differentials are redirecting capital toward non-dollar assets and punishing currency-sensitive exporters.
A stronger franc reduces the reported value of Roche's dollar and other foreign-currency pharmaceutical sales.
- The Patent Cliff Sparks a Biotech Land Grab
ROG.SW in “The Patent Cliff Sparks a Biotech Land Grab”
Not enough historyExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Roche needs its newer portfolio to overcome continuing biosimilar pressure and a series of mixed late-stage clinical outcomes.